Literature DB >> 15637759

Frequencies of the expression of main protein antigens from Helicobacter pylori isolates and production of specific serum antibodies in infected patients.

Jie Yan1, Ya-Fei Mao, Zhe-Xin Shao.   

Abstract

AIM: To investigate the frequencies of the expression of main protein antigens of Helicobacter pylori (H pylori) isolates, such as UreB, VacA, CagA1, HpaA, NapA, FlaA and FlaB and the production of specific antibodies in sera from H pylori-infected patients, and to understand the correlations among the different clinical types of chronic gastritis and peptic ulcer and the infection and virulence of H pylori.
METHODS: H pylori strains in biopsy specimens from 157 patients with chronic gastritis and peptic ulcer were isolated and serum samples from the patients were also collected. The target recombinant proteins rUreB, rVacA, rCagA1, rHpaA, rNapA, rFlaA and rFlaB expressed by the prokaryotic expression systems constructed in our previous studies were collected through Ni-NTA affinity chromatography. Rabbit antisera against rUreB, rVacA, rCagA1, rHpaA, rNapA, rFlaA and rFlaB were prepared by using routine subcutaneous immunization. By using ultrasonic lysates of the isolates as coated antigens, and the self-prepared rabbit antisera as the first antibodies and commercial HRP-labeling sheep anti-rabbit IgG as the second antibody, expression frequencies of the seven antigens in the isolates were detected by ELISA. Another ELISA was established to detect antibodies against the seven antigens in sera of the patients by using the corresponding recombinant proteins as coated antigens, and the sera as the first antibody and HRP-labeling sheep anti-human IgG as the second antibody respectively. Correlations among the different clinical types of chronic gastritis and peptic ulcer and the infection and virulence of H pylori were statistically analysed.
RESULTS: In the 125 isolates of H pylori, the positive rates of UreB, VacA, CagA1, HpaA, NapA, FlaA and FlaB were 100%, 65.6%, 92.8%, 100%, 93.6%, 100% and 99.2% respectively. In the 125 serum samples from the H pylori-infected patients, the positive rates of antibodies against recombinant UreB, VacA, CagA1, HpaA, NapA, FlaA and FlaB were 100%, 42.4%, 89.6%, 81.6%, 93.6%, 98.4% and 92.8% respectively. H pylori strains were isolated from 79.6% (125/157) of the biopsy specimens, but no close correlations among the H pylori infection frequencies and different types of chronic gastritis and peptic ulcer could be found (P>0.05, chi2 = 0.01-0.87). The VacA positive rate (82.40%) in the strains isolated from the specimens of patients with peptic ulcer and the anti-VacA positive rate (54.3%) in the sera from the patients were significantly higher than those (51.5%, 32.3%) from the patients with chronic gastritis (P<0.01, chi2 = 13.19; P<0.05, chi2 = 6.13). When analysis was performed in the different types of chronic gastritis, the VacA in the strains isolated from the specimems of patients with active gastritis showed a higher expression frequency (90.0%) than those from superficial (47.9%) and atrophic gastritis (30.0%) (P<0.05, chi2 = 5.93; P<0.01, chi2 = 7.50). While analysis was carried out in the strains isolated from the specimens with superficial (93.8%) and active gastritis (100%), NapA showed a higher expression frequency compared to that from atrophic gastritis (60.0%) (P<0.01, chi2 = 8.88; P<0.05, chi2 = 5.00).
CONCLUSION: The types of chronic gastritis and peptic ulcer and their severity are not associated with H pylori infection frequency but closely related to the infection frequency of different virulent H pylori strains. The optimal antigens for developing vaccine and diagnostic kit are UreB, FlaA, HpaA, FlaB, NapA and CagA1, but not VacA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15637759      PMCID: PMC4205353          DOI: 10.3748/wjg.v11.i3.421

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  26 in total

1.  Helicobacter pylori cytotoxin induces vacuolation of primary human mucosal epithelial cells.

Authors:  P R Harris; T L Cover; D R Crowe; J M Orenstein; M F Graham; M J Blaser; P D Smith
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

2.  [In vitro study of the biological activities and immunogenicity of recombinant adhesin of Heliobacter pylori rHpaA].

Authors:  Y Chen; J Wang; L Shi
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2001-03-10

3.  Cytotoxicity and motility of Helicobacter pylori.

Authors:  S Watanabe; A Takagi; U Tada; A M Kabir; Y Koga; S Kamiya; T Osaki; T Miwa
Journal:  J Clin Gastroenterol       Date:  1997       Impact factor: 3.062

Review 4.  Helicobacter pylori vaccine strategies--triggering a gut reaction.

Authors:  C Hatzifoti; B W Wren; W J Morrow
Journal:  Immunol Today       Date:  2000-12

5.  Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection.

Authors:  P Ghiara; M Rossi; M Marchetti; A Di Tommaso; C Vindigni; F Ciampolini; A Covacci; J L Telford; M T De Magistris; M Pizza; R Rappuoli; G Del Giudice
Journal:  Infect Immun       Date:  1997-12       Impact factor: 3.441

6.  [Construction of prokaryotic expression system of ureB gene from a clinical isolate of Helicobacter pylori and identification of immunogenicity of the fusion protein].

Authors:  Zhe Chen; Jie Yan; Ya-Fei Mao
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2003-02

7.  [Cloning, expression and identification of hpaA gene from a clinical isolate of Helicobacter pylori].

Authors:  Ya-Fei Mao; Jie Yan; Li-Wei Li
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2003-02

8.  Cloning and expression of a high-molecular-mass major antigen of Helicobacter pylori: evidence of linkage to cytotoxin production.

Authors:  M K Tummuru; T L Cover; M J Blaser
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

9.  Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacter infection in mice.

Authors:  I Corthésy-Theulaz; N Porta; M Glauser; E Saraga; A C Vaney; R Haas; J P Kraehenbuhl; A L Blum; P Michetti
Journal:  Gastroenterology       Date:  1995-07       Impact factor: 22.682

10.  Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer.

Authors:  A Covacci; S Censini; M Bugnoli; R Petracca; D Burroni; G Macchia; A Massone; E Papini; Z Xiang; N Figura
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-15       Impact factor: 11.205

View more
  10 in total

1.  Serum Helicobacter pylori KatA and AhpC antibodies as novel biomarkers for gastric cancer.

Authors:  Bing Zhang; Hai-Lin Li; Qing Fan; Fang Guo; Xi-Yun Ren; Hai-Bo Zhou; Ji-Wei Zhu; Ya-Shuang Zhao; Wen-Jing Tian
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

2.  Complexomics study of two Helicobacter pylori strains of two pathological origins: potential targets for vaccine development and new insight in bacteria metabolism.

Authors:  Cédric Bernarde; Philippe Lehours; Jean-Paul Lasserre; Michel Castroviejo; Marc Bonneu; Francis Mégraud; Armelle Ménard
Journal:  Mol Cell Proteomics       Date:  2010-07-07       Impact factor: 5.911

3.  HpaA is essential for Helicobacter pylori colonization in mice.

Authors:  Elisabet Carlsohn; Johanna Nyström; Ingrid Bölin; Carol L Nilsson; Ann-Mari Svennerholm
Journal:  Infect Immun       Date:  2006-02       Impact factor: 3.441

4.  Serological assays for identification of human gastric colonization by Helicobacter pylori strains expressing VacA m1 or m2.

Authors:  Chandrabali Ghose; Guillermo I Perez-Perez; Victor J Torres; Marialuisa Crosatti; Abraham Nomura; Richard M Peek; Timothy L Cover; Fritz Francois; Martin J Blaser
Journal:  Clin Vaccine Immunol       Date:  2007-01-31

Review 5.  Exploring alternative treatments for Helicobacter pylori infection.

Authors:  Guadalupe Ayala; Wendy Itzel Escobedo-Hinojosa; Carlos Felipe de la Cruz-Herrera; Irma Romero
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

6.  Helicobacter pylori HopE and HopV porins present scarce expression among clinical isolates.

Authors:  Maritza Lienlaf; Juan Pablo Morales; María Inés Díaz; Rodrigo Díaz; Elsa Bruce; Freddy Siegel; Gloria León; Paul R Harris; Alejandro Venegas
Journal:  World J Gastroenterol       Date:  2010-01-21       Impact factor: 5.742

7.  The rOmp22-HpaA fusion protein confers protective immunity against helicobacter pylori in mice.

Authors:  Xueyong Huang; Bianli Xu; Guangcai Duan; Chunhua Song
Journal:  Curr Microbiol       Date:  2013-05-30       Impact factor: 2.188

8.  Helicobacter pylori recombinant UreG protein: cloning, expression, and assessment of its seroreactivity.

Authors:  Akbar Khalilpour; Sabariah Osman; Muhammad Hafiznur Yunus; Amutha Santhanam; Nagarajan Vellasamy; Rahmah Noordin
Journal:  BMC Res Notes       Date:  2014-11-18

9.  Synthetic Lipopeptide Enhances Protective Immunity Against Helicobacter pylori Infection.

Authors:  Ruo-Yi Xue; Mu-Fei Guo; Ling Guo; Chang Liu; Sun Li; Jiao Luo; Li Nie; Lu Ji; Cong-Jia Ma; Da-Qun Chen; Si Sun; Zhe Jin; Quan-Ming Zou; Hai-Bo Li
Journal:  Front Immunol       Date:  2019-06-14       Impact factor: 7.561

10.  Serum Antibodies against Helicobacter pylori Neutrophil Activating Protein in Carriers of IL-4 C-590T Genetic Polymorphism Amplify the Risk of Gastritis and Gastric Cancer.

Authors:  Yeganeh Talebkhan; Mohsen Doozbakhshan; Samaneh Saberi; Maryam Esmaeili; Najmeh Karami; Nazanin Mohajerani; Afshin Abdirad; Mahmoud Eshagh Hosseini; Azin Nahvijou; Mohammad Ali Mohagheghi; Marjan Mohammadi
Journal:  Iran Biomed J       Date:  2016-09-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.